Keros Therapeutics (NASDAQ:KROS) Coverage Initiated by Analysts at Guggenheim

Equities research analysts at Guggenheim initiated coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $96.00 price target on the stock. Guggenheim’s price objective would indicate a potential upside of 72.69% from the stock’s current price.

A number of other research firms have also recently weighed in on KROS. Oppenheimer assumed coverage on Keros Therapeutics in a report on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Truist Financial restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $90.63.

Keros Therapeutics Stock Performance

KROS opened at $55.59 on Monday. The firm has a 50 day moving average price of $49.60 and a 200 day moving average price of $52.86. The company has a market cap of $2.01 billion, a PE ratio of -10.76 and a beta of 1.22. Keros Therapeutics has a 1 year low of $27.02 and a 1 year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same period in the previous year, the business posted ($1.27) earnings per share. On average, sell-side analysts predict that Keros Therapeutics will post -4.78 earnings per share for the current year.

Insider Activity

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after buying an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Keros Therapeutics by 8.8% during the first quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock worth $468,000 after purchasing an additional 574 shares during the last quarter. Arizona State Retirement System lifted its stake in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock worth $369,000 after purchasing an additional 1,130 shares during the last quarter. Finally, American International Group Inc. lifted its stake in Keros Therapeutics by 13.1% during the first quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after purchasing an additional 1,465 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.